BioPharma Dive July 16, 2024
The well-funded startup says drugs AbbVie abandoned last year could be key pieces of a combination regimen with “superior efficacy” to Vertex’s medicines.
Dive Brief:
- Biotechnology startup Sionna Therapeutics has licensed a group of experimental cystic fibrosis drugs from AbbVie, planning to test them in combination regimens that could challenge Vertex Pharmaceuticals’ market-leading medicines.
- In a deal announced Tuesday, Sionna has acquired global rights to two prospects in Phase 2 trials and a third in Phase 1 testing. Financial terms weren’t disclosed, but AbbVie will get an upfront payment and a stake in Sionna. It’s also eligible to receive future development and sales milestones as well as royalties, if any of the drugs ever reach market.
- The transaction adds...
Today's Sponsors
Today's Sponsor